• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促成更有利的交易:一项利用扩展用于健康应用程序编程接口的谷歌趋势对司美格鲁肽全球关注度的信息流行病学研究。

Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.

作者信息

Raubenheimer Jacques Eugene, Myburgh Pieter Hermanus, Bhagavathula Akshaya Srikanth

机构信息

Faculty of Medicine and Health, Sydney Pharmacy School, The University of Sydney, Room 107, A26 (R C Mills bldg.) Science Rd, Sydney, NSW, Australia.

Institute for Intelligent Systems, University of Johannesburg, Johannesburg, South Africa.

出版信息

BMC Glob Public Health. 2024 Sep 17;2(1):63. doi: 10.1186/s44263-024-00095-w.

DOI:10.1186/s44263-024-00095-w
PMID:39681910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11622965/
Abstract

BACKGROUND

Off-label use of semaglutide for non-diabetic weight loss (which regulators have linked to social media promotion) created worldwide supply shortages. We evaluated worldwide semaglutide interest measured by online search behavior to gauge social media and conventional print media reporting's effect on search interest.

METHODS

Using Google Trends Extended for Health (GTEH) multiple sampling, we retrieved regional online interest (ROI) for all countries and extracted timelines and top search queries for January 2021-August 2023 for countries with median ROI ≥ 20 using the "semaglutide" topic. We obtained semaglutide media reporting from the ProQuest database. We estimated the effect of media and within-country semaglutide interest on between-country interest with Granger causality analysis. We determined changepoints for trends within each country with joinpoint regression. We determined prominent themes in search queries for each country with natural language processing thematic analysis.

RESULTS

Twenty-seven countries were included. Most countries showed an increase in semaglutide interest over time, with Canada and the USA showing the largest sustained interest. Most of the search interest arose from 2022 onwards. Granger's analysis showed that media coverage could only partially explain interest, and interest in some countries partially preceded interest in others, with the UK and Germany showing strong relationships between news reports and lagged search interest. Joinpoint analysis identified up to four significant within-country changepoints. Most countries showed significant positive weekly trends in 2021-2022, although uptrends in search interest varied considerably between countries. One episode of the Dr. Oz show (TV media event) coincided with strong peaks in numerous countries. Natural language processing of top search queries showed some agreement between countries and country-specific themes. Weight loss was a major theme in most countries, while a diabetes theme was generally absent or weak. Some countries (Australia, Chile, South Africa, UK) had themes for buying Ozempic from (named) local retailers, and Germany had a theme related to buying Ozempic without a script.

CONCLUSIONS

GTEH data provided insights into global search interest in semaglutide and regional variation. Studies focusing on specific countries which include social media data can elucidate specific drivers behind the surge in off-label use of semaglutide.

摘要

背景

司美格鲁肽用于非糖尿病患者减肥的超说明书用药(监管机构认为这与社交媒体推广有关)导致全球供应短缺。我们通过在线搜索行为评估了全球对司美格鲁肽的关注度,以衡量社交媒体和传统印刷媒体报道对搜索兴趣的影响。

方法

使用谷歌健康趋势扩展版(GTEH)多次抽样,我们检索了所有国家的区域在线兴趣(ROI),并使用“司美格鲁肽”主题提取了2021年1月至2023年8月期间ROI中位数≥20的国家的时间线和热门搜索查询。我们从ProQuest数据库获取了司美格鲁肽的媒体报道。我们用格兰杰因果分析估计了媒体和国内司美格鲁肽兴趣对国家间兴趣的影响。我们用连接点回归确定了每个国家趋势的变化点。我们用自然语言处理主题分析确定了每个国家搜索查询中的突出主题。

结果

纳入了27个国家。大多数国家对司美格鲁肽的兴趣随时间增加,加拿大和美国表现出最大的持续兴趣。大多数搜索兴趣从2022年开始出现。格兰杰分析表明,媒体报道只能部分解释兴趣,一些国家的兴趣部分先于其他国家,英国和德国的新闻报道与滞后的搜索兴趣之间存在很强的关系。连接点分析确定了每个国家内多达四个显著的变化点。大多数国家在2021 - 2022年显示出显著的每周正趋势,尽管各国搜索兴趣的上升趋势差异很大。奥兹医生秀(电视媒体事件)的一集与许多国家的强烈峰值同时出现。热门搜索查询的自然语言处理显示各国之间有一些一致性以及特定国家的主题。减肥是大多数国家的一个主要主题,而糖尿病主题通常不存在或较弱。一些国家(澳大利亚、智利、南非、英国)有从(指定的)当地零售商购买奥泽米皮克的主题,德国有一个与无处方购买奥泽米皮克相关的主题。

结论

GTEH数据提供了对全球司美格鲁肽搜索兴趣及区域差异的见解。关注特定国家并纳入社交媒体数据的研究可以阐明司美格鲁肽超说明书用药激增背后的具体驱动因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/a7dd97e649c8/44263_2024_95_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/0d45c1a8b34d/44263_2024_95_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/b75ca5bffb35/44263_2024_95_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/ca684959f8d0/44263_2024_95_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/637404a14cbb/44263_2024_95_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/a7dd97e649c8/44263_2024_95_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/0d45c1a8b34d/44263_2024_95_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/b75ca5bffb35/44263_2024_95_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/ca684959f8d0/44263_2024_95_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/637404a14cbb/44263_2024_95_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d479/11622965/a7dd97e649c8/44263_2024_95_Fig5_HTML.jpg

相似文献

1
Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.促成更有利的交易:一项利用扩展用于健康应用程序编程接口的谷歌趋势对司美格鲁肽全球关注度的信息流行病学研究。
BMC Glob Public Health. 2024 Sep 17;2(1):63. doi: 10.1186/s44263-024-00095-w.
2
Understanding Health Communication Through Google Trends and News Coverage for COVID-19: Multinational Study in Eight Countries.通过谷歌趋势和新冠疫情新闻报道理解健康传播:八国跨国研究。
JMIR Public Health Surveill. 2021 Dec 21;7(12):e26644. doi: 10.2196/26644.
3
Public and Research Interest in Telemedicine From 2017 to 2022: Infodemiology Study of Google Trends Data and Bibliometric Analysis of Scientific Literature.2017 年至 2022 年的远程医疗的公众和研究兴趣:谷歌趋势数据的信息流行病学研究和科学文献的文献计量分析。
J Med Internet Res. 2024 May 16;26:e50088. doi: 10.2196/50088.
4
Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study.在一项为期12个月的回顾性分析中,利用谷歌趋势统计数据评估人群对胰高血糖素样肽-1受体激动剂用于减肥的关注度:一项信息流行病学与信息监测研究
Cureus. 2024 Oct 15;16(10):e71569. doi: 10.7759/cureus.71569. eCollection 2024 Oct.
5
Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.公众对胰高血糖素样肽-1激动剂(司美格鲁肽)用于美容减肥的超说明书用药的兴趣:一项谷歌趋势分析
Aesthet Surg J. 2023 Dec 14;44(1):60-67. doi: 10.1093/asj/sjad211.
6
Decreasing public interest in social psychiatry: An infodemiological study of worldwide Google search volumes from 2004 to 2021.公众对社会精神病学兴趣降低:2004 年至 2021 年全球谷歌搜索量的信息流行病学研究。
Int J Soc Psychiatry. 2023 Feb;69(1):216-220. doi: 10.1177/00207640221090960. Epub 2022 Apr 20.
7
Online Health Information Seeking for Mpox in Endemic and Nonendemic Countries: Google Trends Study.流行国家和非流行国家关于猴痘的在线健康信息搜索:谷歌趋势研究
JMIR Form Res. 2023 Apr 13;7:e42710. doi: 10.2196/42710.
8
Semaglutide (Ozempic) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss.司美格鲁肽(Ozempic)在丹麦2018年至2023年的使用情况——用户趋势及减肥的非标签处方用药情况
Clin Epidemiol. 2024 Apr 25;16:307-318. doi: 10.2147/CLEP.S456170. eCollection 2024.
9
Global utilization of online information for substance use disorder: An infodemiological study of Google and Wikipedia from 2004 to 2022.全球范围内对物质使用障碍相关信息的在线利用:2004 年至 2022 年谷歌和维基百科的信息流行病学研究。
J Nurs Scholarsh. 2023 May;55(3):665-680. doi: 10.1111/jnu.12844. Epub 2022 Nov 8.
10
"Googling" for Cancer: An Infodemiological Assessment of Online Search Interests in Australia, Canada, New Zealand, the United Kingdom, and the United States.通过谷歌搜索癌症:对澳大利亚、加拿大、新西兰、英国和美国在线搜索兴趣的信息流行病学评估
JMIR Cancer. 2016 May 4;2(1):e5. doi: 10.2196/cancer.5212.

引用本文的文献

1
[Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].[通过胰高血糖素样肽-1受体激动剂实现的快速体重减轻作为一种生活方式现象及其对整形美容医学的影响]
HNO. 2025 Aug 6. doi: 10.1007/s00106-025-01653-w.
2
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes.2型糖尿病患者中GLP-1受体激动剂和司美格鲁肽处方的真实世界比较结果
medRxiv. 2025 Jun 4:2025.06.03.25328908. doi: 10.1101/2025.06.03.25328908.
3
Health Beliefs and Obesity Bias as Determinants of Attitudes Toward the Rising Tides of GLP-1 Medications: Mounjaro and Ozempic.

本文引用的文献

1
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.从世界卫生组织关于司美格鲁肽、利拉鲁肽和自杀的数据中进行不均衡分析。
JAMA Netw Open. 2024 Aug 1;7(8):e2423385. doi: 10.1001/jamanetworkopen.2024.23385.
2
How to 'drug' our way out of the obesity crisis (or not): the roll-out of semaglutide.如何通过药物(或无法通过药物)摆脱肥胖危机:司美格鲁肽的推出。
Br J Gen Pract. 2024 Apr 25;74(742):218. doi: 10.3399/bjgp24X737241. Print 2024 May.
3
Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort.
健康观念和肥胖偏见作为对GLP-1药物(如Mounjaro和Ozempic)使用增加趋势态度的决定因素
Diabetes Metab Syndr Obes. 2025 May 3;18:1389-1409. doi: 10.2147/DMSO.S518994. eCollection 2025.
4
GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks.糖尿病与体重减轻中的胰高血糖素样肽-1受体激动剂:创新与风险的双刃剑
Front Clin Diabetes Healthc. 2025 Jan 9;5:1530811. doi: 10.3389/fcdhc.2024.1530811. eCollection 2024.
5
2024 at BMC Global and Public Health: a year in review.2024年《BMC全球与公共卫生》回顾:一年总结
BMC Glob Public Health. 2024 Dec 23;2(1):86. doi: 10.1186/s44263-024-00119-5.
胰高血糖素样肽-1受体激动剂相关的胃肠道不良事件:美国国立卫生研究院“我们所有人”队列的横断面分析
Pharmaceuticals (Basel). 2024 Feb 2;17(2):199. doi: 10.3390/ph17020199.
4
Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon.自然减肥还是“奥兹姆皮克脸”:揭开社交媒体现象的神秘面纱。
J Drugs Dermatol. 2024 Jan 1;23(1):1367-1368. doi: 10.36849/JDD.7613.
5
Association of semaglutide with risk of suicidal ideation in a real-world cohort.在真实世界队列中,司美格鲁肽与自杀意念风险的关联。
Nat Med. 2024 Jan;30(1):168-176. doi: 10.1038/s41591-023-02672-2. Epub 2024 Jan 5.
6
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).胰高血糖素样肽-1受体激动剂(GLP-1 RAs)与自杀倾向之间的关联:向美国食品药品监督管理局不良事件报告系统(FAERS)提交的报告
Expert Opin Drug Saf. 2024 Jan;23(1):47-55. doi: 10.1080/14740338.2023.2295397. Epub 2023 Dec 19.
7
GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach.胰高血糖素样肽-1受体激动剂及相关心理健康问题:采用混合方法从一系列社交媒体平台获得的见解
Brain Sci. 2023 Oct 24;13(11):1503. doi: 10.3390/brainsci13111503.
8
Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders.社交媒体在药物警戒中的应用:患者报告为物质使用障碍的胰高血糖素样肽 1(GLP-1)受体激动剂的临床研究提供信息的潜力。
J Stud Alcohol Drugs. 2024 Jan;85(1):5-11. doi: 10.15288/jsad.23-00318. Epub 2023 Oct 30.
9
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.胰高血糖素样肽-1受体激动剂用于减肥时胃肠道不良事件的风险
JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574.
10
A narrative review of approved and emerging anti-obesity medications.已批准和新出现的抗肥胖药物的叙述性综述。
Saudi Pharm J. 2023 Oct;31(10):101757. doi: 10.1016/j.jsps.2023.101757. Epub 2023 Aug 24.